Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

368.85 +2.65 (+0.72%)

Streaming Delayed Price Updated: 11:01 AM EST, Feb 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? ↗

Today 11:05 EST

Wegovy might be getting more competition soon.

Via The Motley Fool

Topics Intellectual Property

The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)

Today 9:36 EST

As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization...

Via Finterra

Topics Earnings Economy Intellectual Property

Why Is Amgen Stock Falling Premarket? ↗

Today 4:29 EST

Wall Street’s updated price targets on Amgen imply a wide range from about 16% downside to a 15% upside from the stock’s last close.

Via Stocktwits

Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products ↗

February 04, 2026

Via Stocktwits

Amgen Inc (NASDAQ:AMGN) Beats Q4 2025 Estimates and Provides Strong 2026 Revenue Guidance ↗

February 03, 2026

Via Chartmill

AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout ↗

January 21, 2026

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

February 04, 2026

Via Chartmill

Wednesday's session: top gainers and losers in the S&P500 index ↗

February 04, 2026

Via Chartmill

AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook

February 04, 2026

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at...

Via StockStory

Amgen (AMGN) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Amgen (AMGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025

February 03, 2026

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of...

Via StockStory

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Amgen (AMGN) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 01, 2026

Via StockStory

Topics Artificial Intelligence

Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. ↗

January 28, 2026

Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Via The Motley Fool

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

Via MarketMinute

Topics Earnings Economy Government

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks

January 25, 2026

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Amgen (NASDAQ:AMGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles

January 23, 2026

Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

Via MarketMinute

Topics Economy

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Via MarketMinute

Topics Earnings Economy Intellectual Property

The 50.9 Mirage: Is the Manufacturing Expansion a True Recovery or a Tariff-Induced Sugar High?

January 20, 2026

The American manufacturing sector has finally crossed the threshold into expansion territory, with the latest Institute for Supply Management (ISM) Manufacturing PMI rising to 50.9. This mark...

Via MarketMinute

Topics Economy Supply Chain World Trade

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

2 Dividend Stocks to Buy and Hold For 10 Years ↗

January 19, 2026

They are unlikely to resort to dividend cuts anytime soon.

Via The Motley Fool

Topics Intellectual Property

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

Via Finterra

Topics Economy

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

January 18, 2026

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers.

Via StockStory

Topics Artificial Intelligence

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their...

Via MarketMinute

Topics Artificial Intelligence Economy

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Via PredictStreet

Topics Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.